Read More References

front cover of Alice In Wonderland book

Never Imagine Yourself Not To Be Otherwise

1. Murray, GI, Taylor, MC, McFadyen MCE, et al: Tumor-specific expression of cytochrome P450 CYP1B1. Canc Res, 1997; 57(14): 3026-3031.

2. McFadyen MC, Breeman S, Payne S, et al: Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem, 1999; 47: 1457-1464.

3. Gibson P, Gill JH, Khan PA, et al: Cytchrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: Implications for drug development. Mol Canc Therap, 2003; 2(6): 527-534.

4. McFadyen, MCE, Melvin, WT, Murray GI: Cytochrome P450 CYP1B1 activity in renal cell carcinoma. Brit J Canc, 2004; 91(5): 966-971.

old open book from the outside

Open Book

5. Maecker B, von Bergwelt-Baildon MS, Anderson KS, et al: Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients. Clin Exper Immunol, 2005; 141(3): 558-562.

6. Tokizane T, Shiina H, Igawa M, et al: Cytchrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin Canc Res, 2005; 11(16): 5793-5801.

7. Oyama T, Morita M, Isse T, et al: Immunohistochemical evaluation of cytochrome P450 (CYP) and p53 in breast cancer. Frontiers Biosci, 2005; 10: 1156-1161.

8. Downie D, McFadyen MCE, Rooney, PH, et al: Profiling cytochrome P450 expression in ovarian cancer: Identification of prognostic markers. Clin Canc Res, 2005; 11(20): 7369-7375.

9. Potter GA, Burke MD: Salvestrols- Natural Products with Tumour Selective Activity. J Orthomol Med, 2006; 21(1): 34-36.

open Shakespeare book


10. Tan HL, Butler PC, Burke MD, et al: Salvestrols: A New Perspective in Nutritional Research. J Orthomol Med, 2007; 22(1): 39-47.

11. Chu OA, Chung Y, Pepper MA: Juice processing incorporating resin treatment. USPTO, Patent No 7,108,887, 2006.

12. Daniel O, Meier, MS, Schlatter J, et al: Selected phenolic compounds in cultivated plants: Ecologic functions, health implications, and modulation by pesticides. Environ Health Perspect, 1999; 107: 109-114.

an open book from the bottom

Your Book


Sincerely, Mother

Physiologist, Scientist, Author




2 Responses to Read More References

  1. Gerry Potter says:

    Heres another important reference thats harder to find:

    British Journal of Cancer, 86 (Suppl 1), S12, 2002.

    G.A. Potter, Cancer Drug Discovery Group, School of Pharmacy, De Montfort University, Leicester LE1 9BH.

    A case is presented for the enzyme CYP1B1 functioning as a tumour suppressor enzyme which acts via the bioactivation of natural dietary compounds into growth inhibitory substances. The enzyme CYP1B1 is a human cytochrome P450 enzyme belonging to the CYP1 family, which comprises three members CYP1A1, CYP1A2, and CYP1B1. CYP1 family enzymes are known to metabolise xenobiotics and to activate procarcinogens into active carcinogens. CYP1B1 is of interest since it is highly expressed in many different types of human tumour (e.g. breast, colon, lung) but is not expressed in the normal tissue. This has led some researchers to conclude that CYP1B1 is involved in the cause of tumours due to its carcinogen activating ability. However this is a very simplistic view and does not explain why the CYP1B1 enzyme should be present in tumours in the first place, nor how it can be expressed in such a wide varity of tumours irrespective of their different oncogenic origins. We have developed an alternative hypothesis whereby CYP1B1 is functioning in an opposite sense, being there to destroy the tumour cells. Here we propose that CYP1B1 functions as a tumour suppressor enzyme through natural prodrug bioactivation. Preliminary evidence for this hypothesis has now been obtained and natural prodrugs with cancer preventative properties have been identified.
    1Murray, G.I., Taylor, M.C., McFadyen, M.C.E., McKay, J.A., Greenlee, W.F., Burke, M.D. & Melvin, W.T. Cancer Res., 57, 3026-3031, 1997
    2Potter, G.A., Patterson, L.H. & Burke, M.D. Aromatic hydroxylation activated (AHA) prodrugs. US Patent 6,214,886, 2001
    3G.A. Potter, L.H. Patterson, E. Wanogho, P.J. Perry, P.C. Butler, T. Ijaz, K.C. Ruparelia, J.H. Lamb, P.B. Farmer, L.A. Stanley, and M.D. Burke,
    Br. J. Cancer, 86, 774-778, 2002

    • Mother says:

      Hello again Gerry,
      I am so very grateful that you post these helpful articles here on my blog for me to pass around. I am doing my very best to get them read by as many people as I am in contact with. I do live in Florida where there are many elderly people therefore many people are being diagnosed with cancers of many kinds. I will continue to spread the word.
      Thank you again,
      Physiologist, Scientist, Author.

Leave a Reply...Mother likes to hear from you.

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s